Drug
SHR- A1811
SHR- A1811 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
recruiting125%
not_yet_recruiting375%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_3
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
NCT07528716
not_yet_recruitingphase_2
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
NCT07307287
not_yet_recruitingphase_2
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
NCT07047443
recruitingphase_2
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
NCT05896020
Clinical Trials (4)
Showing 4 of 4 trials
NCT07528716Phase 3
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
NCT07307287Phase 2
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
NCT07047443Phase 2
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
NCT05896020Phase 2
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4